Manolis Athanasios J, Iraklianou Stella, Pittaras Andreas, Zaris Michael, Tsioufis Konstantinos, Psaltiras George, Psomali Demetra, Foussas Stefanos, Gavras Irene, Gavras Haralambos
The Hypertension Clinic, Tzanion Hospital, Piraeus, Greece.
Am J Hypertens. 2005 Jan;18(1):18-22. doi: 10.1016/j.amjhyper.2004.08.014.
Diabetes mellitus (DM) is known to cause increased arterial wall stiffness and increased cardiovascular risk, even in the absence of hypertension. This study was designed to investigate whether use of an angiotensin-converting enzyme (ACE) inhibitor may improve arterial stiffness in normotensive diabetics, using pulse wave velocity (PWV) as a surrogate marker.
We studied 42 patients (26 with type 2 DM, aged 56.5 +/- 9 years, 16 with type 1 DM, aged 41.5 +/- 11 years) by measuring PWV at baseline (compared to 15 age- and gender-matched normal subjects) and after 6 months of treatment with perindopril (4 mg/d).
At baseline, PWV was significantly higher in DM patients versus controls (13.09 +/- 2.59 v 9.5 +/- 1.6 m/sec, respectively, P < .001). After 6 months, PWV decreased significantly to 11.68 +/- 3.08 m/sec (P < .003) for the whole DM group. However, the results were driven by the change in the younger type 1 DM (from 12.59 +/- 1.59 to 10.35 +/- 2.21 m/sec, P < .001), whereas in the type 2 DM it was insignificant (from 13.37 +/- 3.0 to 12.42 +/- 3.28 m/sec). Blood pressure and other hemodynamic and biochemical parameters remained unchanged.
The results demonstrate that ACE inhibition can improve arterial elasticity and hence risk of cardiovascular complications even in normotensive diabetics. This short treatment was effective only in younger patients with type 1 diabetes, suggesting that early initiation of therapy before the onset of advanced structural alterations is likely to be more cardioprotective.
糖尿病(DM)已知会导致动脉壁僵硬度增加以及心血管风险升高,即便在无高血压的情况下亦是如此。本研究旨在探讨使用血管紧张素转换酶(ACE)抑制剂是否可改善血压正常的糖尿病患者的动脉僵硬度,采用脉搏波速度(PWV)作为替代标志物。
我们研究了42例患者(26例2型糖尿病患者,年龄56.5±9岁,16例1型糖尿病患者,年龄41.5±11岁),在基线时(与15例年龄和性别匹配的正常受试者相比)以及培哚普利(4 mg/d)治疗6个月后测量PWV。
基线时,糖尿病患者的PWV显著高于对照组(分别为13.09±2.59 vs 9.5±1.6 m/秒,P<.001)。6个月后,整个糖尿病组的PWV显著降至11.68±3.08 m/秒(P<.003)。然而,结果是由较年轻的1型糖尿病患者的变化所驱动(从12.59±1.59降至10.35±2.21 m/秒,P<.001),而在2型糖尿病患者中则不显著(从13.37±3.0降至12.42±3.28 m/秒)。血压及其他血流动力学和生化参数保持不变。
结果表明,即使在血压正常的糖尿病患者中,ACE抑制也可改善动脉弹性,从而降低心血管并发症风险。这种短期治疗仅对较年轻的1型糖尿病患者有效,提示在晚期结构改变发生之前尽早开始治疗可能更具心脏保护作用。